These Alzheimer’s drugs were supposed to revolutionize the way we fight the disease. The reality is more complicated.

A scientific report has raised questions about how much Leqimbi and Kisunla — the “breakthrough” Alzheimer’s drugs that have hit the market in the last few years — really help slow the disease.

Source

MarketWatch

Read full article at MarketWatch

Opens original article in a new tab

ADB chief warns of yen pressure from Japan's too-slow rate hikes

about 1 hour agoRead more →

EconomyDaily Composite

Yahoo Finance

Vermillion Wealth Management Loads Up On Foreign Debt With a Purchase of DFGX Shares Worth $3.4 Million

about 1 hour agoRead more →

Bloomberg Markets

Orban Loss, Meloni Setback Signal Left’s EU Return, Ribera Says

The defeat of Hungary’s Viktor Orban is a warning conservative European leaders who may be tempted to align closely with Donald Trump and Vladimir Putin, according to the European Commission’s most senior Social Democrat official.

about 2 hours agoRead more →

EconomyDaily Composite

Bloomberg Markets

How JLL is Embracing Artificial Intelligence | C-Suite Saturdays

With a legacy spanning 243 years, JLL is now navigating a landscape transformed by Artificial Intelligence. JLL President and Global CEO Christian Ulbrich joins David Gura and Christina Ruffini on Bloomberg This Weekend to discuss how the firm stays ahead of the curve. (Source: Bloomberg)

about 3 hours agoRead more →

Related Economy Stories

ADB chief warns of yen pressure from Japan's too-slow rate hikes

Vermillion Wealth Management Loads Up On Foreign Debt With a Purchase of DFGX Shares Worth $3.4 Million

Orban Loss, Meloni Setback Signal Left’s EU Return, Ribera Says

How JLL is Embracing Artificial Intelligence | C-Suite Saturdays